37 results on '"Li, Junling"'
Search Results
2. Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
3. Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial
4. Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
5. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China
6. Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China
7. Efficacy of dacomitinib in patients with EGFR ‐mutated NSCLC and brain metastases
8. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
9. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
10. Study protocol: A single‐arm, multicenter, phaseIItrial of camrelizumab plus apatinib for advanced nonsquamousNSCLCpreviously treated with first‐line immunotherapy
11. Efficacy and safety profile of combining programmed cell death‐1 ( PD ‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer ( NSCLC )
12. Concurrent chemotherapy and first‐generation epidermal growth factor receptor ( EGFR )‐tyrosine kinase inhibitors ( TKIs ) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
13. Establishment of a prospective multicenter cohort for advanced non‐small cell lung cancer in China (CAPTRA‐Lung study)
14. Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China.
15. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
16. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer
17. Correlation analysis of mesenchymal–epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China
18. Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
19. Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
20. Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection
21. Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
22. Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy.
23. Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
24. Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
25. Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
26. Favorable predictors for survival in advanced ALK ‐positive non‐small cell lung cancer patients beyond crizotinib resistance
27. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer
28. Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study
29. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
30. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer
31. Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial
32. Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis
33. Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer
34. Histological subtypes of lung cancer in Chinese women from 2000 to 2012
35. Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancer
36. Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
37. Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.